CureVac shares plunge by €7bn as data show vaccine hopeful falls short

Shares fell more than 44% in Frankfurt trade, after the company said its Covid-19 vaccine was only 47% effective in an early trial analysis

CureVac lost almost half its value after a preliminary analysis of a large study found its Covid-19 vaccine fell short of the high efficacy bar set by other messenger RNA shots. File picture

CureVac lost almost half its value after a preliminary analysis of a large study found its Covid-19 vaccine fell short of the high efficacy bar set by other messenger RNA shots.

The shares plunged more than 44% in Frankfurt trade, wiping out almost €7bn in market value, after the company said the vaccine was only 47% effective in an early trial analysis.